

Supplementary figures

Figure S1. Reduced mRNA/protein ratio in M170I NFIL3 patients. (A) CD14⁺ monocytes and CD16⁺ monocytes were sorted from controls and patients, prior to NFIL3 qPCR. (B) NFIL3 expression was assessed on CD14⁺ monocytes and CD16⁺ monocytes by flow cytometry. (C) The ratio of protein/mRNA was calculated for patients and healthy controls using the qPCR and flow cytometry data. Mean and individual values shown.




Figure S2. M170I mutation in NFIL3 causes decreased protein stability. HEK293T cells were transfected with FLAG-tagged NFIL3-GFP, using either the wildtype or M170I mutant form. **(A)** Transfected cells were imaged with DAPI and anti-FLAG antibodies, with representative images of wildtype NFIL3 and **(B)** M170I NFIL3 transfections. Scale bar = 50 μ m. **(C)** Quantification of FLAG-NFIL3 immunofluorescence in wildtype and mutant transfected cells (n=92,104 cells). Mean \pm Standard deviation. **(D)** Transfected cells were assessed for plasmid copy number, using qPCR quantification of a plasmid-encoded ncRNA. **(E)** Transfected cells were assessed for NFIL3 mRNA expression using qPCR quantification and **(F)** NFIL3 protein expression, using flow cytometry. Mean and individual values shown.




Figure S3. Enhanced histological damage following arthritis induction in NFIL3 knockout mice. Wildtype and *Nfil3*^{-/-} mice were injected with serum from K/BxN mice (n=9/group). Mice were scored for histological damage on day 7. Mean±SD; * p<0.05.




Figure S4. Visualization of expression of specific lineage markers (colored single cells) on tSNE plot projecting 6,908 PBMCs from patient and control.




Figure S5. Validation of single cell RNAseq gene expression changes. CD14⁺ monocytes were sorted from P1 and age-matched gender-matched control. **(A)** Expression of NFIL3 target genes *STX11*, *TGFB1*, *CSF2RB*, *CEBPG*, *CD224* normalized to *HPRT*, *RPL0*, *ACTB* mRNA. Patient (P1) and age and gender matched control are shown. Below the qPCR expression data the log₂ fold-change observed in the scRNA seq dataset is listed, for comparison. **(B)** Expression of IL1 β mRNA in patients and controls, normalized to *HPRT*, *RPL0*, *ACTB* mRNA.




Figure S6. Differentially expressed gene sets between patient and control. Each leukocyte cluster was assessed for differentially expressed genes. Gene set analysis with GSEA was performed on the differentially expressed genes within each leukocyte cluster, with a false discovery rate of 25% used to identify up- and down-regulated pathways. **(A)** Naïve T cells, **(B)** Naïve B cells, **(C)** activated CD4 T cells, **(D)** memory B cells, **(E)** CD14⁺ monocytes, **(F)** CD1c⁺ DCs, **(G)** activated CD8 T cells, **(H)** CD56^{bright} NK cells, **(I)** CD56^{dim} NK cells, **(J)** $\gamma\delta$ T cells, **(K)** CD16⁺ monocytes), **(L)** activated monocytes, **(M)** proliferating cells.

